Meeting
2020 ASCO Virtual Scientific Program
ASPEN: Results of a phase III randomized trial of zanubrutinib versus ibrutinib for patients with Waldenström macroglobulinemia (WM).
Presenter
Constantine Si Lun Tam, MD,MBBS,FRACP,FRCPA
Peter MacCallum Cancer Centre, Melbourne, St Vincent’s Hospital, Fitzroy, University of Melbourne, Parkville and Royal Melbourne Hospital
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Videos & Slides Details
Session Type
Oral Abstract Session
Session Title
Hematologic Malignancies—Lymphoma and Chronic Lymphocytic Leukemia
Track
Hematologic Malignancies
Sub Track
Non-Hodgkin Lymphoma
Clinical Trial Registration Number
NCT03053440
Citation
J Clin Oncol 38: 2020 (suppl; abstr 8007)
DOI
10.1200/JCO.2020.38.15_suppl.8007
Abstract #
8007
Abstract Disclosures
Similar Videos & Slides
Videos & Slides
2022 ASCO Annual Meeting
ASPEN: Long-term follow-up results of a phase 3 randomized trial of zanubrutinib (ZANU) versus ibrutinib (IBR) in patients with Waldenström macroglobulinemia (WM).
Speaker: Constantine Si Lun Tam, MD, FRCPA
Videos & Slides
2021 ASCO Annual Meeting
Efficacy and safety of zanubrutinib versus rituximab-based chemoimmunotherapy in Waldenström macroglobulinemia (WM): Matching-adjusted indirect comparisons.
Speaker: Jorge J. Castillo, MD
Videos & Slides
2020 ASCO Virtual Scientific Program
Trial in progress: a phase II, multicenter, single-arm study of zanubrutinib (BGB-3111) in patients with previously treated chronic lymphocytic leukemia/small lymphocytic lymphoma intolerant of prior treatment with ibrutinib.
Speaker: Ian Flinn, MD, PhD
Videos & Slides
2020 ASCO Virtual Scientific Program
Three-year follow-up of treatment-naïve and previously treated patients with Waldenström macroglobulinemia (WM) receiving single-agent zanubrutinib.
Speaker: Constantine Si Lun Tam, MD,MBBS,FRACP,FRCPA